Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?

TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 3, 2026

Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?

TransMedics' rapid revenue growth and cheaper valuation face rising margin pressure as heavy investment raises execution risks.

Zacks Investment Research • Sep 3, 2026

TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX).

GlobeNewsWire • Sep 3, 2026

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX

NEW YORK, Aug. 31, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). If you currently own shares of TransMedics Group stock, please visit the firm's website at https://rosenlegal.com/cases/transmedics-group-inc/join for more information.

PRNewsWire • Sep 1, 2026

TransMedics to Present at Upcoming September Investor Conferences

ANDOVER, Mass., Aug. 31, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences.

PRNewsWire • Aug 31, 2026

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

PRNewsWire • Aug 25, 2026

TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX

New York, New York--(Newsfile Corp. - August 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). If you currently own shares of TransMedics Group stock, please visit the firm's website at https://rosenlegal.com/cases/transmedics-group-inc/join for more information.

Newsfile Corp • Aug 19, 2026

TransMedics Targets $2B Opportunity With Kidney Push, European Expansion

TransMedics Group NASDAQ: TMDX outlined its growth strategy at Canaccord Genuity's 46th Annual Global Growth Conference, highlighting investments in kidney transplantation, European expansion, next-generation technology and broader adoption in heart and lung transplantation.

MarketBeat • Aug 18, 2026

TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into TransMedics Group, Inc. (NasdaqGM: TMDX) (“TransMedics” or the “Company”). TransMedics is a medical technology company focused on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. The Company operates the Organ Care System,.

Business Wire • Aug 17, 2026

TransMedics: Margins Down, Concentration Up, Trials Delayed

Q2's headline beat was driven by low-margin logistics and pricing, not by more organs moving through the platform; service outgrew product by 16.4 pp. Revenue is increasingly concentrated in the liver (78% of organ revenue), while the heart barely grew, and the lung fell 42% year-over-year. The heart and lung growth catalysts, ENHANCE and DENOVO, are delayed, gated by FDA enrollment, and contribute minimally while dragging margins.

Seeking Alpha • Aug 6, 2026